Freenome

Freenome is a private biotechnology company breaking barriers to early cancer detection with a suite of blood tests built on its intelligent screening platform. Freenome’s multimodal approach combines molecular biology and assays with computational biology, machine learning and multiple data types to tune into cancer’s subtlest cues, even at the earliest stages of disease. By providing a more convenient option, Freenome’s blood test for the early detection of CRC has the potential to boost screening adherence rates and improve accessibility for people in all communities. With the convenience of a standard blood draw, Freenome aims to empower everyone to access recommended cancer screenings.